General Information
Drug ID
DR00217
Drug Name
Gabapentin
Synonyms
1-(Aminomethyl)-cyclohexaneacetic acid; 1-(Aminomethyl)cyclohexaneacetic acid; 2-[1-(aminomethyl)cyclohexyl]acetic acid; Aclonium; Apo-Gabapentin; Apotex brand of gabapentin; Aventis brand of gabapentin; DDS-2003; DM-1796; DM-5689; G-154; GBN; GOE 2450; Gabapen; Gabapentin (JAN/USAN/INN); Gabapentin (Neurontin); Gabapentin GR; Gabapentin Hexal; Gabapentin Stada; Gabapentin [USAN:INN:BAN]; Gabapentin-ratiopharm; Gabapentina; Gabapentine; Gabapentine [INN-French]; Gabapentinium; Gabapentino; Gabapentino [INN-Spanish]; Gabapentino [Spanish]; Gabapentinum; Gabapentinum [INN-Latin]; Gabapetin; Go 3450; Goe-3450; Hexal brand of gabapentin; Neurontin; Neurontin (TN); Novo-Gabapentin; Novopharm brand of gabapentin; PMS-Gabapentin; Parke Davis brand of gabapentin; Pfizer brand of gabapentin; Pharmascience brand of gabapentin; Ratiopharm brand of gabapentin; Serada; Stadapharm brand of gabapentin; Vultin; Warner-Lambert brand of gabapentin; [1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
Drug Type
Small molecular drug
Indication Partial seizures [ICD11: 8A68.0] Approved [1]
Therapeutic Class
Analgesics
Structure
3D MOL 2D MOL
Formula
C9H17NO2
Canonical SMILES
C1CCC(CC1)(CC(=O)O)CN
InChI
InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)
InChIKey
UGJMXCAKCUNAIE-UHFFFAOYSA-N
CAS Number
CAS 60142-96-3
Pharmaceutical Properties Molecular Weight 171.24 Topological Polar Surface Area 63.3
Heavy Atom Count 12 Rotatable Bond Count 3
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 3
XLogP
-1.1
PubChem CID
3446
PubChem SID
10321252 , 11111218 , 11112806 , 11113327 , 11466889 , 11468009 , 11486558 , 11528594 , 12012796 , 15171186 , 17405144 , 24278159 , 25623436 , 29222580 , 3206533 , 46506529 , 47291223 , 47365305 , 47515412 , 47589087 , 48035236 , 48413201 , 48416046 , 49655262 , 49698669 , 49833701 , 50100248 , 50103936 , 50103937 , 50519620 , 53777688 , 56312982 , 56365854 , 5651496 , 57321804 , 7847398 , 7887769 , 7979342 , 8028266 , 8028269 , 8152192 , 85174424 , 85209452 , 85231060 , 855579 , 87560508 , 89649772 , 90340599 , 91146476 , 92125867
ChEBI ID
ChEBI:42797
TTD Drug ID
D0J0ZS
DT(s) Transporting This Drug LAT1 Transporter Info L-type amino acid transporter 1 Substrate [2]
OCT-2 Transporter Info Organic cation transporter 2 Substrate [3]
OCTN1 Transporter Info Organic cation/carnitine transporter 1 Substrate [4]
Drug-Transporter Activity Data
Drug-Transporter Activity Data LAT1 Transporter Info Km = 530 microM hCMEC/D3 cells-LAT1 [2]
References
1 Gabapentin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol. 2013 Jun 1;85(11):1672-83.
3 Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010 May;69(5):498-507.
4 Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008 Mar;83(3):416-21.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.